Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial-MedSci.cn

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Cruz, LR; Baladron, I; Rittoles, A; Diaz, PA; Valenzuela, C; Santana, R; Vazquez, MM; Garcia, A; Chacon, D; Thompson, D; Perera, G; Gonzalez, A; Reyes, R; Torres, L; Perez, J; Valido, Y; Rodriguez, R; Vazquez-Bloomquist, DM; Rosales, M; Ramon, AC; Perez, GV; Guillen, G; Muzio, V; Perera, Y; Perea, SE

Perea, SE (corresponding author), Ctr Genet Engn & Biotechnol, Havana 10600, Cuba.

Abstract

The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19. Anti-SARS-Co......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

科室

工具

服务